• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Domestic Research Enhancement Act of 2017 endorsed by many

Domestic Research Enhancement Act of 2017 endorsed by many

April 11, 2017
CenterWatch Staff

The Domestic Research Enhancement Act of 2017 (H.R. 1234), which modernizes the R&D tax credit to recognize the essential role contract research now plays in the development of new pharmaceuticals, biologics and medical devices, has been introduced by Rep. Pat Meehan (R-PA) and co-sponsors Rep. George Holding (R-NC) and G.K. Butterfield (D-NC).

“The life sciences industry is a very important economic driver in both Pennsylvania and North Carolina and contract CROs are a major contributor with ACRO members employing more than 20,000 research staff in these two states,” said ACRO Chairman John Hubbard, Ph.D., president and CEO of Bioclinica, headquartered in Doylestown, Pennsylvania. “We commend Reps. Meehan, Holding and Butterfield for introducing legislation that promotes good jobs and domestic innovation.”

The legislation would enable firms conducting contract research across industries to claim a portion of the R&D Tax Credit that is now abandoned when a research sponsor, seeking greater efficiency, employs a CRO.

“In many ways, North Carolina was the birthplace of the CRO industry,” said Cynthia Verst, president of Clinical Operations at QuintilesIMS and an ACRO Board member. “QuintilesIMS is extremely proud of the positive impact CROs have in the state and the 100+ countries where we conduct operations.”

“The life sciences sector is one of the largest employers in southeastern Pennsylvania and a prime driver of our economic growth and dynamism,” said Congressman Meehan. “Contract research firms play a critical role, employing some 6,000 Pennsylvanians. The Domestic Research Enhancement Act will help make American life sciences firms more competitive on the global stage, spur more investment and innovation into groundbreaking new cures, and strengthen our regional economy.”

Meehan sits on the key House Ways and Means Committee, the body in the House of Representatives responsible for tax policy.

Hubbard said, “The Domestic Research Enhancement Act of 2017 will enable the industry to continue to grow in the state, supporting jobs, innovation and the homegrown development of new treatments and cures for patients in need.”

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing